Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback